Form 4: Athira Pharma's Chief Scientific Officer Reports Stock Transactions Following RSU Vesting

Kevin Church, Chief Scientific Officer of Athira Pharma, reports acquisition and disposal of company stock related to ESPP purchases and RSU vesting, including sales to cover tax obligations.

Summary

• Kevin Church, the Chief Scientific Officer of Athira Pharma, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On May 20, 2024, Church acquired 4,953 shares of common stock through the Employee Stock Purchase Plan (ESPP) at a price of $1.34 per share.
• On September 3, 2024, 10,000 restricted stock units (RSUs) vested following the public readout of topline results from the LIFT-AD Phase 2/3 clinical trial.
• On September 5, 2024, Church sold 2,525 shares at an average price of $0.566 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Church beneficially owns 92,684 shares of Athira Pharma common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to employee compensation and tax obligations. The vesting of RSUs tied to clinical trial milestones is a positive sign, but the stock sale is a neutral event.

Positives

• The vesting of RSUs indicates progress in Athira Pharma's clinical trials, specifically the LIFT-AD Phase 2/3 trial.

Negatives

• The sale of shares to cover tax obligations could be perceived negatively, although it's a standard practice.

Risks

• The stock sales to cover tax obligations may exert downward pressure on the stock price.

Future Outlook

The vesting schedule of the remaining RSUs is tied to the completion of enrollment and public readout of topline results of the LIFT-AD Phase 2/3 clinical trial.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and provide transparency into their transactions in company stock. The vesting of RSUs tied to clinical trial milestones aligns executive compensation with the company's research and development progress.

Comparison to Industry Standards

• Similar to other biotech companies, Athira uses RSUs to incentivize key employees and align their interests with the company's long-term success.
• The 'sell to cover' practice for tax obligations is a standard procedure in many companies with equity compensation plans.

Stakeholder Impact

• Shareholders may be interested in the insider transactions as an indicator of management's confidence in the company.
• Employees participating in the ESPP are directly impacted by the stock price and the terms of the plan.

Next Steps

• Continued monitoring of insider transactions.
• Tracking the progress of Athira Pharma's clinical trials, particularly the LIFT-AD Phase 2/3 trial.

Key Dates